Impact of out-of-pocket costs on prescription fills among new initiators of biologic therapies for rheumatoid arthritis

Journal of Managed Care and Specialty Pharmacy

Volumn 22, Issue 2, 2016, Pages 122-130

  Hopson, Sari ^a   Saverno, Kim ^a   Liu, Larry Z ^b   Al Sabbagh, Ahmad ^b   Orazem, John ^b   Costantino, Mary E ^a   Pasquale, Margaret K ^a  

^a Formerly of Comprehensive Health Insights Inc   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; PRESCRIPTION DRUG;

ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; COST; ECONOMICS; FEMALE; HEALTH CARE COST; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; COSTS AND COST ANALYSIS; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; PRESCRIPTION DRUGS; RETROSPECTIVE STUDIES;

EID: 84961738582     PISSN: 23760540     EISSN: 23761032     Source Type: Journal    
DOI: 10.18553/jmcp.2016.14261     Document Type: Article

References (20)

1. Sullivan SD. The promise of specialty pharmaceuticals: are they worth the price?. J Manag Care Pharm. 2008;14(4 Suppl):S3-6. Available at: http://www.amcp.org/data/jmcp/JMCPSupp_S3-S6.pdf.
2. Desai RJ, Rao JK, Hansen RA, Fang G, Maciejewski ML, Farley JF. Predictors of treatment initiation with tumor necrosis factor-α inhibitors in patients with rheumatoid arthritis. J Manag Care Spec Pharm. 2014;20(11):1110-20. Available at: http://www.amcp.org/JMCP/2014/November/18725/1033.html.
3. Gleason PP, Starner CI, Gunderson BW, Schafer JA, Sarran HS. Association of prescription abandonment with cost share for high-cost specialty pharmacy medications. J Manag Care Pharm. 2009;15(8):648-58. Available at: http://www.amcp.org/data/jmcp/648-658.pdf.
4. Pasquale MK, Louder AM, Deminski MC, Chambers RB, Haider S. Outof-pocket costs and prescription reversals with oral linezolid. Am J Manag Care. 2013;19(9):734-40. Available at: http://www.ajmc.com/publications/issue/2013/2013-1-vol19-n9/Out-of-Pocket-Costs-and-Prescription-Reversals-With-Oral-Linezolid/.Accessed November 17, 2015.
5. Dismuke CE, Egede LE. Medicare Part D prescription drug program: benefits, unintended consequences and impact on health disparities. J Gen Intern Med. 2013;28(7):860-61. Available at: http://link.springer.com/article/10.1007%2Fs11606-013-2423-3.Accessed November 17, 2015.
6. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient out-ofpocket payments matter? Arthritis Rheum. 2008;59(10):1519-26. Available at: http://onlinelibrary.wiley.com/doi/10.1002/art.24114/abstract;jsessionid=8FF6562D97E8F478BCDD9B0F5518DECF.f01t02. Accessed November 17, 2015.
7. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic diseasemodifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762-84. Available at: http://onlinelibrary.wiley.com/doi/10.1002/art.23721/abstract.Accessed November 17, 2015.
8. Karaca-Mandic P, Joyce GF, Goldman DP, Laouri M. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis. Health Serv Res. 2010;45(5 Pt 1):1227-50. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1475-6773.2010.01117.x/abstract. Accessed November 17, 2015.
9. Gleason PP, Alexander GC, Starner CI, et al. Health plan utilization and costs of specialty drugs within 4 chronic conditions. J Manag Care Pharm. 2013;19(7):542-48. Available at: http://www.amcp.org/JMCP/2013/September_2013/17100/1033.html.
10. Fautrel B, Clarke AE, Guillemin F, et al. Costs of rheumatoid arthritis: new estimates from the human capital method and comparison to the willingness-to-pay method. Med Decis Making. 2007;27(2):138-50.
11. Bansback N, Marra CA, Finckh A, Anis A. The economics of treatment in early rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2009;23(1):83-92.
12. Cardarelli WJ. Implications for managed care and specialty pharmacy in rheumatoid arthritis. Am J Manag Care. 2012;18(13 Suppl):S315-S24. Available at: http://www.ajmc.com/publications/supplement/2012/ACE006_12dec_RA/ACE006_12dec_Cardarelli_S315to24/.Accessed November 17, 2015.
13. Pasma A, Van't Spijker A, Hazes JM, Busschbach JJ, Luime JJ. Factors associated with adherence to pharmaceutical treatment for rheumatoid arthritis patients: a systematic review. Semin Arthritis Rheum. 2013;43(1):18-28.
14. Schmajuk G, Trivedi AN, Solomon DH, et al. Receipt of diseasemodifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans. JAMA. 2011;305(5):480-86. Available at: http://jama.jamanetwork.com/article.aspx?articleid=645416.Accessed November 19, 2015.
15. Solomon DH, Yelin E, Katz JN, Lu B, Shaykevich T, Ayanian JZ. Treatment of rheumatoid arthritis in the Medicare Current Beneficiary Survey. Arthritis Res Ther. 2013;15(2):R43-R43. Available at: http://arthritisresearch.com/content/15/2/R43. Accessed November 19, 2015.
16. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730-740. Available at: http://www.ajmc.com/publications/issue/2005/2005-11-vol11-n11/Nov05-2205p730-740/.Accessed November 19, 2015.
17. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.
18. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12(1):21-28. Available at: http://www.ajmc.com/publications/issue/2006/2006-01-vol12-n1/Jan06-2244p21-28/.Accessed November 19, 2015.
19. Thomson S, Schang L, Chernew ME. Value-based cost sharing in the United States and elsewhere can increase patients' use of high-value goods and services. Health Aff (Millwood). 2013;32(4):704-12.
20. Tsai AG, Williamson DF, Glick HA. Direct medical cost of overweight and obesity in the USA: a quantitative systematic review. Obes Rev. 2011;12(1):50-61.